XFOR: X4 Pharmaceuticals Inc. Company Value to Net Income
X4 Pharmaceuticals (XFOR) specializes in the therapy of rare immune disorders, utilizing AI and automated screening to accelerate drug discovery. This PE chart reflects a value of -4.20. The business relies on proprietary formulas with low production costs, while streamlined coordination with factories and robotic warehouses ensure the uninterrupted production and delivery of medications.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_XFOR_-_X4-Pharmaceuticals_-_PE-Multiple "XFOR: X4 Pharmaceuticals Business Payback Period 07/04/2022 - 11/11/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for X4 Pharma (XFOR)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio X4 Pharmaceuticals|XFOR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital X4 Pharmaceuticals, Inc|XFOR - Company Debts|Debt to Book Value Ratio X4 Pharmaceuticals, Inc.|XFOR - Company Long-Term Debts|Short-Term Debt X4 Pharmaceuticals|Immediate Liquidity Ratio x4pharma.com
- earnings and market multiples details:
XFOR - Company Profit|Future Profit X4 Pharmaceuticals|XFOR - Company Value to Net Income|Future Price to Earnings X4 Pharmaceuticals Inc.|XFOR - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple X4 Pharmaceuticals, Inc.|XFOR - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) X4 Pharmaceuticals|XFOR - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months x4pharma.com|XFOR - Earnings per share increase in current year|Net earnings per share growth forecast for next year X4 Pharmaceuticals
Comprehensive company analysis:x4pharma.com XFOR
To objectively assess the issuer's value, a manager must correlate market capitalization with net income to determine the price per unit of earnings. By analyzing the annual P/E of X4 Pharmaceuticals (XFOR), an investor can identify asset overvaluation, particularly when the stock price growth of X4 Pharmaceuticals (XFOR) outpaces the actual financial gains from the commercialization of Xolremdi and the expansion of the drug's insurance coverage.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL: Price to Earnings Ratio|TRML (Tourmaline) - Price to Earnings Multiple|Price to Earnings Multiple Precigen, Inc.|Price to Earnings Ratio pharming.com|NKTR - Company Value to Net Income|Price to Earnings Ratio UPB|ZBIO - Market Cap to Net Income|P/E Multiple Immunome Bio (IMNM)|Company Value to Net Income Gossamer Bio, Inc.|P/E Multiple kalvista.com KALV|Septerna - P/E Multiple|PVLA: Price to Earnings Ratio|Company Value to Net Income Savara Corp SVRA|RIGL (Rigel Corp) - Price to Earnings Ratio|Price to Earnings Ratio ANAB|P/E Multiple astriatx.com|P/E Multiple ENGN|P/E Multiple RAPT Therapeutics Inc. (RAPT)|Aerovate Therapeutics - Price to Earnings Ratio|P/E Multiple Aclaris Therapeutics, Inc ACRS|KYTX (Kyverna Therapeutics) - Market Cap to Earnings|tizianalifesciences.com (TLSA) - Price to Earnings Ratio|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Biosciences Inc.|Theratechnologies Inc (THTX) - Market Price to Net Income Ratio|P/E Multiple Avalo Therapeutics Inc|ELDN (Eledon Pharmaceuticals) - Business Payback Period|P/E Multiple agenusbio.com (AGEN)|Climb Bio - Price to Earnings Ratio|P/E Multiple Zura Bio Ltd ZURA|aTyr - P/E Multiple|ADAG: Price to Earnings Ratio|ikenaoncology.com (IMA) - Price to Earnings Ratio|STTK (Shattuck Labs) - Price to Earnings Ratio|EQ: Business Payback Period|Price to Earnings Ratio Connect Pharma (CNTB)|Price to Earnings Multiple Immunic, Inc. IMUX|P/E Multiple atarabio.com (ATRA)|InflaRx (IFRX) - Market Cap to Net Income|Adicet Bio Inc. - Price to Earnings Ratio|CELU (Celularity Corp) - Market Cap to Earnings|INMB: Price to Earnings Ratio|Company Value to Net Income Barinthus Bio BRNS|KZR (Kezar Life Sciences Inc) - Price to Earnings Ratio|Market Cap to Net Income SAB Biotherapeutics SABS|P/E Multiple akaritx.com|Enlivex Therapeutics (ENLV) - Company Value to Net Income|P/E Multiple q32bio.com (QTTB)|P/E Multiple GOVX (GeoVax Labs Inc)|Edesa Biotech Corp - Price to Earnings Ratio|Company Value to Net Income iBio, Inc. (IBIO)|CARM: Price to Earnings Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - Price to Earnings Ratio|Bolt Biotherapeutics, Inc. (BOLT) - P/E Multiple|HCWB (HCW Biologics, Inc.) - P/E Multiple|Price to Earnings Ratio Aptevo (APVO)|AIM ImmunoTech Inc. (AIM) - Company Value to Net Income|P/E Multiple aditxt.com (ADTX)|Business Payback Period GRI|XORTX Therapeutics Inc - Price to Earnings Ratio|HIND: Price to Earnings Ratio|REVB: Price to Earnings Ratio|INDP (Indaptus Therapeutics) - Price to Earnings Ratio|Price to Earnings Ratio scinai.com|CALI (CalciMedica Inc) - P/E Multiple|Price to Earnings Ratio AFMD|Price to Earnings Multiple Allakos Inc. ALLK|P/E Multiple hookipapharma.com (HOOK)|IGMS: Market Cap to Earnings|ITOS - Price to Earnings Ratio|Ocean Biomedical (OCEA) - Price to Earnings Multiple|TCBP (TC BioPharm (Holdings) Plc) - Price to Earnings Multiple|THRD (Third Harmonic Bio, Inc) - Price to Earnings Ratio
